Late-breaking data showcase the benefits of abbott's minimally invasive devices for people with leaky heart valves

New data presented at transcatheter cardiovascular therapeutics (tct) 2023 from the triluminate™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with triclip™, an investigational device in the u.s. one-year outcomes from the expand g4 study, simultaneously published in jacc: cardiovascular interventions , reinforce durable safety and effectiveness of mitraclip™ with significant mitral regurgitation reduction abbott park, ill., oct. 24, 2023 /prnewswire/ -- abbott (nyse: abt) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease.
ABT Ratings Summary
ABT Quant Ranking